Immix Biopharma, Inc.
For the period ended Dec 31, 2025. Filed Mar 25, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 25, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 and 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized on this 25 th day of March, 2026.
/s/ Ilya Rachman
Ilya Rachman
Chief Executive Officer and Chief Scientific Officer
(Principal Executive Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ Ilya Rachman | Chief Executive Officer (Principal Executive Officer), Chief Scientific Officer and Chairman of the Board of Directors | March 25, 2026 |
| Ilya Rachman | ||
| /s/ Gabriel Morris | Chief Financial Officer, President and Director | March 25, 2026 |
| Gabriel Morris | (Principal Financial and Accounting Officer) | |
| /s/ Jason Hsu | Director | March 25, 2026 |
| Jason Hsu | ||
| /s/ Magda Marquet | Director | March 25, 2026 |
| Magda Marquet | ||
| /s/ Helen C. Adams | Director | March 25, 2026 |
| Helen C. Adams | ||
| /s/ Carey Ng | Director | March 25, 2026 |
| Carey Ng | ||
| /s/ Jane Buchan | Director | March 25, 2026 |
| Jane Buchan | ||
| /s/ Yekaterina Chudnovsky | Director | March 25, 2026 |
| Yekaterina Chudnovsky | ||
| /s/ Nancy Chang | Director | March 25, 2026 |
| Nancy Chang | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.